3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
43
Terminated
10
Unknown
4
Withdrawn
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
73
Head & Neck
51
Genitourinary
51
Thoracic
48
CNS
42
Breast
24
Gynecologic
13
Sarcoma
12
Lymphoid
10
Tumor-Agnostic
7
Dermatologic
5
Plasma cell
3
Other solid neoplasm
2
Other hematologic neoplasm
2
Other
2
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Graft vs Host Disease
1
Interventions
venetoclax
33
fludarabine
32
Cyclophosphamide
31
Azacitidine
29
Specimen Handling
27
Biopsy
20
Cytarabine
19
fludarabine phosphate
15
Whole-Body Irradiation
15
Stem Cell Transplantation
15
Decitabine
15
ruxolitinib
14
Tacrolimus
14
Melphalan
14
Busulfan
14
Mycophenolic Acid
13
Injections
11
asciminib
10
decitabine and cedazuridine drug combination
9
Thiotepa
8
Methotrexate
8
Hematopoietic Stem Cell Transplantation
8
X-Rays
7
Granulocyte Colony-Stimulating Factor
7
Magnetic Resonance Spectroscopy
6
Idarubicin
6
Filgrastim
6
Cyclosporine
6
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
6
tagraxofusp
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Radiotherapy
×
Myeloid
×
Clear all
NCT04678401
2025-10-20
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Phase 1
Recruiting
30 enrolled